SAT0118 SAFETY AND EFFICACY OF ALTERNATE-DAY CORTICOSTEROIDS AS ADJUNCTIVE THERAPY IN RHEUMATOID ARTHRITIS
Background: Corticosteroids are often used for treating rheumatoid arthritis. However, minimizing adverse events while maximizing efficacy remains challenging. An alternate-day corticosteroid dose is known to decrease adverse events. Objectives: To investigate the safety and efficacy of an alternate-day corticosteroid dose for treating rheumatoid arthritis. Methods: We have conducted a retrospective cohort study among patients over 18-year-old who started oral corticosteroids (prednisolone and methylprednisolone) as treatment of rheumatoid arthritis from 2005 to 2014 at St. Luke's International Hospital, a tertiary-level community teaching hospital in Tokyo, Japan. Patients were included if they met the American College of Rheumatology/European League Against Rheumatism 2010 classification criteria for rheumatoid arthritis, and had positive anti-cyclic citrullinated peptide antibody. They were excluded for a history of corticosteroid use for other diseases, or if they were lost to follow-up within 1 year after starting corticosteroids. We divided patients into a daily corticosteroid group (QD) and an alternate-day corticosteroid group (QOD). Patients who received both daily and alternate-day corticosteroids were assigned to the daily group. We investigated the percentage of patients without any infection within 1 year after starting corticosteroids. We have conducted multivariate logistic regression model analysis to calculate adjusted odds ratio for QD/QOD to the outcome. We also investigated the mean decrease in C-reactive protein (CRP) at 1 month as a marker of short-term effectiveness, and the percentage of patients free from corticosteroid at one year, using student's t-test. Results: In total, 139 patients were analysed (69 in the QD group, 70 in the QOD group). The maximum dose of corticosteroid in one year was not significantly different in two groups (11.4±7.7 mg/day VS 10.1±5.3 mg/day; P=0.267), and the mean daily dose of corticosteroid in one year was significantly higher in the QD group (6.1±4.4 mg/day vs 3.9±1.7 mg/day; P<0.01).The percentage of patients without any infection was 49.2% in QD group, and 75.7% in QOD group. Univariate analysis showed QD group is significantly associated with higher incidence of infection (P=0.001). After multivariate analysis adjusted with age, gender, initial CRP value, mean daily dose of corticosteroid in one year, use of biologic DMARDs, and duration of rheumatoid arthritis, the odds ratio of QD for any infection in 1 year was 3.9 (95% confidence interval [CI], 1.7-8.8; P=0.001).The mean decrease of CRP at 1 month was 1.5 mg/dl in QD group, and 1.1 mg/dl in QOD group (P=0.435).The percentage of patients free from corticosteroids at one year was 26.1% in QD group, and 58.6% in QOD group (P<0.01). Kaplan-Meier plot showed that QD group patients are more difficult to become free from corticosteroid (log-rank test: p<0.01).
Conclusions:
Alternate-day corticosteroid dose has a lower adverse event rate and is as effective as a daily corticosteroid dose for treating rheumatoid arthritis. Background: Prior studies have suggested higher rates of preterm birth in pregnancies to women with rheumatoid arthritis. Objectives: We sought to identify differences in the pregnancy outcomes of women with and without RA, and pregnancies that occurred prior to and following RA diagnosis. Methods: A cross-sectional survey was completed by 75 women with RA age-matched to 75 women without RA. Information collected about each prior pregnancy included: pregnancy outcome (spontaneous abortion, stillbirth, elective termination, ectopic pregnancy, or live birth); the timing of delivery; infant anomalies; methotrexate exposure in pregnancy; and whether the pregnancy was planned. Simple statistics were used to compare pregnancy outcomes between women with and without RA and pregnancies prior to and following RA diagnosis. Results: The majority of women with RA (83%) and controls (64%) were white, and 11% of women with RA and 28% of controls were African American. About half of controls and 31% of women with RA had education beyond college. The average age at the time of the survey was 32 years (SD: 5) in both RA patients and controls, and the average age at RA diagnosis was 23 years (SD: 10). There were 76 pregnancies in 40 women with RA and 99 pregnancies in 33 healthy controls (see table) . The overall rates of live birth, spontaneous abortion, and ectopic pregnancies were similar between groups; there were no stillbirths. The rate of elective termination was significantly different, with 9% of RA and 30% of control pregnancies terminated (p=0.005). The large majority of the terminations in women with RA occurred prior to diagnosis. The higher frequency of unplanned pregnancy among the controls (38% unplanned RA vs 67% unplanned controls, p=0.0002) likely contributed to this higher termination rate. Of unplanned pregnancies, 45% were terminated in controls, 33% in pre-RA pregnancies, and 9% in post-RA pregnancies. No planned pregnancies were terminated. Three pregnancies in women with RA were exposed to methotrexate (2 unplanned, 1 planned) resulting in 2 spontaneous abortions and 1 live birth, born at term without any reported abnormalities. The rates of preterm birth and infant abnormalities did not differ significantly between those with and without RA, though among women with RA, all preterm births and infant abnormalities occurred after RA diagnosis. Each of the RA preterm births was delivered between 31-34 weeks gestation. Preeclampsia was more common in women with RA, but did not differ significantly between pregnancies prior to and after RA diagnosis. A total of 41% of the post-RA pregnancies had an adverse pregnancy outcome (miscarriage, preterm delivery, or infant abnormality), compared to 13% of pre-RA pregnancies (p=0.01) and 20% of control pregnancies (p=0.01).
Women with RA, overall, had similar rates of miscarriage, stillbirth, and ectopic pregnancy compared to healthy women, but pregnancies that occurred after RA diagnosis had higher rates of these adverse outcomes. More pregnancies in women with RA were planned, leading to a lower rate of elective termination. Background: While dramatic progress has been made in this decade with treatments for rheumatoid arthritis (RA), such as methotrexate (MTX) and biological agents, concern about the safety, including the occurrence of malignancy, of these highly effective drugs still exists in daily clinical practice. There has not been an evident association between the use of biological agents and the occurrence of malignancy in most reports from clinical trials 1 and observational studies 2 , although MTX use might be associated with the development of malignant lymphoma, called MTX-associated lymphoproliferative disorder 3 , in patients with RA. In an analysis of risk factors for overall and site-specific malignancies in Japanese patients with RA, higher disease activity was identified to be a risk factor for overall malignancies (hazard ratio [HR] 1.10, 95% CI 1.02-1.19), suggesting that tight control of RA disease activity would reduce the occurrence of malignancies in patients with RA 4 . However, the risk of malignancies with RA treatments including MTX and biological agents was not assessed in that analysis. Objectives: We investigated the association between the occurrence of malignancies (overall and malignant lymphoma) and drug use (MTX and biological agents) in a large observational cohort of Japanese patients with RA over a long-term period. Methods: Among Japanese patients with RA enrolled in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort from April 2000 to September 2013, data for all malignancies were extracted from patients' self-reports and confirmed by medical records. Data for malignancies occurring in patients who dropped out of the IORRA study during the subsequent three months were also collected from medical information from affiliated hospitals. We analysed whether MTX and biological agents were risk factors for overall malignancy and malignant lymphoma using a marginal structural Cox proportional hazards model 5 adjusted for age, gender, smoking history, body mass index, RA disease duration, rheumatoid factor positivity and disease activity (28-joint disease activity score). Results: Among 11,106 Japanese patients with RA representing 68,483 personyears, 507 overall malignancies, including 68 malignant lymphomas, were confirmed. Neither MTX nor biological agent use was a significant risk factor for overall malignancy, with an HR (95% CI) of 1.18 (0.77-1.81) and 1.01 (0.65-1.57), respectively, or for malignant lymphoma, with an HR (95% CI) of 1.17 (0.55-2.48) and 1.26 (0.43-3.64), respectively. Conclusions: The use of MTX and biological agents was not significantly associated with the occurrence of overall malignancy or malignant lymphoma during long-term longitudinal observation of Japanese patients with RA. Background: Health status in rheumatoid arthritis (RA), as measured by Health Assessment Questionnaire -Disability Index (HAQ-DI), has been established as a relevant quantitative measure to assess and monitor the disease (1). Current RA therapy has shown improvement in patient-reported outcomes, but more data on specific factors influencing health status are needed (2) . Objectives: To assess the relationship between functional disability and clinical factors in patients with RA, using the HAQ score. Methods: Cross-sectional study in patients with RA according to the ACR classification criteria from three Brazilian University Hospitals. Demographic and comprehensive clinical data, including components of metabolic profile were collected. Blood pressure, weight and height were determined in the assessment visit and recent laboratory data were assessed from medical records. Disease activity was evaluated by the Disease Activity Score in 28 joints (DAS28) and functional disability was assessed by the HAQ-DI, considering an index>0.5 as disability. All analyses were performed using Stata for MAC 12.0 software. Variables that achieved a p-value<0.3 in the univariate analysis were considered as candidates to take part of a multivariate binomial logistic model, and in this model, variables were considered as statistically significant at the 0.05 significance level (3) . Results: 453 patients were included, 380 (83.9%) women, mean age 55.7 (±12) years, 356 (79.1%) Caucasian, and mean disease duration of 13.3 (±9) years. Methotrexate were used by 73.5% of the sample. Mean DAS28 was 3.9 (±1.4), mean HAQ score was 1.11 (±0.77), and 23.9% of the patients had HAQ score>0.5. Dyslipidemia, diabetes mellitus (DM), high blood pressure (HBP) and family history of premature cardiovascular disease occurred in 28.6%, 12.8%, 51% and 21.4% of the patients, respectively. Mean body mass index (BMI) was 27.1 (±4.9) kg/m 2 . In multivariate analysis age, DAS28, tobacco use, and diabetes mellitus were independently associated with HAQ>0.5 (TABLE 1). DAS28 -disease activity score in 28 joints; BMI -body mass index; OR -odds ratio.
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SAT0121 COMORBITIES AND DISEASE ACTIVITY ARE RELEVANT FOR FUNCTIONAL DISABILITY IN RHEUMATOID ARTHRITIS
Conclusions:
Our results depicted that distinct factors could reflect in the functional status response in RA patients. This is relevant since it may influence the clinicaly important difference when evaluating the HAQ response in populations with diverse cultural features and different comorbidities prevalence.
